+ cardiac progenitor cells (CPCs) are 2 promising cell types being evaluated for patients with heart failure (HF) secondary to ischemic cardiomyopathy. No information is available in humans about the relative efficacy of MSCs and CPCs and whether their combination is more efficacious than either cell type alone.
C ell therapy has recently emerged as a potential novel approach to the treatment of heart failure (HF) caused by chronic ischemic cardiomyopathy (coronary artery disease and old myocardial infarction [MI] ), hereby referred to as ischemic HF. Many studies have explored the use of various types of stem or progenitor cells in patients with chronic ischemic HF, 1 with encouraging results. [1] [2] [3] [4] However, since the studies performed to date have been relatively small, definitive demonstration of therapeutic efficacy awaits the results of large, well-designed phase III trials. Two of the most promising types of cells being considered for patients with ischemic HF are bone marrow (BM) mesenchymal stem cells (MSCs) 4 and c-kit + cardiac progenitor cells (CPCs). 1, 5 No information is available about the relative efficacy Another important question is whether the combination of MSCs and CPCs is more efficacious than either cell type alone. A beneficial interaction between these cells types is suggested by preclinical evidence that transplantation of MSCs promotes proliferation of endogenous CPCs, suggesting that this may be an important mechanism for the salutary effects of MSC administration. 7 Indeed, when MSCs and CPCs were combined in preclinical models, the therapeutic effects were additive and thus superior to those of either cell type alone. 24, 25 The concept of combinatorial stem cell therapy is conceptually attractive but has never been tested in humans.
CONCERT-HF (Combination of Mesenchymal and ckit + Cardiac Stem Cells As Regenerative Therapy for Heart Failure) is a phase II trial aimed at addressing the aforementioned issues by assessing the feasibility, safety, and efficacy of MSCs and CPCs, alone and in combination, in patients with ischemic HF. Using a randomized, double-blinded, placebocontrolled, multicenter, adaptive design, CONCERT-HF addresses several important questions: Is combined treatment with autologous MSCs and CPCs feasible and safe in patients with ischemic HF? Do MSCs and CPCs, given alone or in combination, alleviate LV dysfunction, reduce scar size, improve quality of life, and augment functional capacity in this population? Is either cell type more effective than the other? Is the combination of MSCs and CPCs superior to MSCs alone or CPCs alone in terms of therapeutic efficacy? 
Novelty and Significance
What Is Known?
• Bone marrow mesenchymal stem cells (MSCs) ameliorate left ventricular dysfunction and reduce scar size in preclinical models of chronic ischemic cardiomyopathy, and several clinical trials suggest that MSCs are safe and beneficial in patients with chronic heart failure (HF) of ischemic cause.
• c-kit + cardiac progenitor cells (CPCs) also attenuate left ventricular dysfunction and remodeling in animal models of chronic ischemic cardiomyopathy. The SCIPIO trial (Cardiac Stem Cell Infusion In Patients With Ischemic Cardiomyopathy) has suggested benefit in patients with ischemic HF, but the study was not designed to establish efficacy.
• When MSCs and CPCs are combined in preclinical models, the therapeutic effects are additive and thus superior to those of either cell type alone. However, neither the concept of combinatorial stem cell therapy nor the relative efficacy of MSCs versus CPCs has been tested in humans.
What New Information Does This Article Contribute?
• We describe CONCERT-HF (Combination of Mesenchymal and c-kit + Cardiac Stem Cells As Regenerative Therapy for Heart Failure), a phase II trial that assesses the feasibility, safety, and efficacy of autologous MSCs and CPCs, given alone or in combination, in patients with ischemic HF.
• CONCERT-HF is the first trial to evaluate the effects of CPCs in ischemic HF with a multicenter, randomized, double-blind protocol powered for efficacy.
• CONCERT-HF is the first trial to compare the relative effects of MSCs and CPCs in patients in the same study.
• CONCERT-HF is the first trial to evaluate a combination of 2 different cell types.
• Other innovative features of CONCERT-HF include the adaptive design and the use of magnetic resonance imaging in patients with devices. 
Methods

Study Population
On completion of the CONCERT-HF trial, results will be publicly available at http://www.clinicaltrials.gov and data will be available by request to the corresponding author of the final results article. Inclusion and exclusion criteria are summarized in Tables 1 and 2 
Study Design
The primary objectives are to assess (1) whether autologous MSCs and CPCs, alone or in combination, can be manufactured and delivered to patients with ischemic HF (feasibility); (2) whether the administration of MSCs and CPCs, alone or in combination, is welltolerated (safety); and (3) whether MSCs and CPCs, delivered alone or in combination, improve LV function, quality of life, and functional capacity, and reduce scar size (efficacy). The planned total sample size is 160 patients enrolled in 2 stages. In stage 1 (open-label, lead-in study) 16 patients (expanded to 18) were randomized 1:1 to either a standard-of-care control group (ie, they did not undergo harvest, mapping, or injection procedures) or combination therapy (MSCs+CPCs, as described below for stage 2). Stage 1 participants were followed for 3 months to complete safety and functional assessments. After review of the 3-month data by a National Heart, Lung, and Blood Institute Data and Safety Monitoring Board, approval was granted to proceed with stage 2 (vide infra). Patients randomized to MSCs+CPCs in stage 1 were followed for 12 months for safety. Those randomized to the standard-of-care control group had the option to be evaluated for enrollment in stage 2.
Stage 2 is a phase II, double-blind, randomized, placebo-controlled trial designed to evaluate the feasibility, safety, and efficacy of MSCs alone, CPCs alone, and their combination compared with placebo as well as each other in patients with ischemic HF (Figure) . Using an adaptive design, stage 2 patients (n=144) are randomized 
Baseline Testing, Randomization, and Tissue Harvesting
Within 60 days of written informed consent, patients undergo baseline testing (Table 3) . Any eligible patients are randomized via an online database created and maintained by the Data Coordinating Center and undergo, on the same day, BM aspiration (BMA) and right heart catheterization (RHC; all groups) and right ventricular endocardial biopsy (EMB; only in the CPCs alone and MSCs+CPCs groups). A total of ≈90 mL of BM is harvested from the posterior iliac crest. On arrival at the local cell processing laboratory, BM samples undergo quality control tests including sterility (aerobic, anaerobic, and fungal cultures), nucleated cell count, and viability (Trypan Blue). Fresh BM samples are shipped to both the central cell manufacturing facility for production of MSCs and, with appropriate consent, to the Cardiovascular Cell Therapy Research Network Biorepository core (BRC). 32 In patients assigned to the CPCs alone and MSCs+CPCs groups, EMB is performed during RHC. Up to 6 endomyocardial samples are obtained to achieve ≈20 mg total tissue. Fresh EMB samples are shipped to the central cell manufacturing facility for isolation and expansion of CPCs. Two transthoracic 2-dimensional (2D) echoes without contrast are done on the day of harvest for all study patients: (1) a pre-RHC procedure echo to assess for preexisting pericardial effusion and (2) a post-RHC procedure performed within 6 hours postprocedure. To minimize the risk of serious adverse events, RHC procedures are canceled or terminated if the patient's New York Heart Association class deteriorates to class IV, if the right ventricular or pulmonary artery systolic pressure is ≥60 mm Hg, or if the pulmonary capillary wedge pressure is ≥35 mm Hg. Furthermore, the RHC procedure is temporarily halted and the suitability of the patient for continuation re-evaluated if systemic blood pressure is <80 mm Hg (change from baseline), heart rate is >100 beats per minute (change from baseline), either right ventricular or pulmonary artery systolic pressures are 50 to 59 mm Hg, or pulmonary capillary wedge pressure is 30 to 34 mm Hg.
Cell Manufacturing
MSCs and CPCs are manufactured by the central cell manufacturing facility at the University of Miami Miller School of Medicine's Interdisciplinary Stem Cell Institute.
MSCs are manufactured using each patient's own BM. The mononuclear cells are isolated using a density gradient with lymphocyte separation medium. The low-density cells are collected from the gradient and plated for further expansion. After 14 days of culture, passage zero (P0) cells are harvested by enzymatic treatment and expanded into 60 flasks. These flasks are incubated for a week and the MSCs are harvested again (P1 cells). The P1 cells are then washed and total viable cell counts are determined for cell dosing. Samples of MSC products are characterized to assure that they meet predetermined specifications with regard to cell count, phenotype, potency, mycoplasma testing, and other quality control tests (Table 4) . Mononuclear cells of participants randomized to CPCs alone or to placebo are cryopreserved and shipped to the BRC. Media from the final MSC passage before product cryopreservation is likewise cryopreserved and sent to BRC.
In patients randomized to the CPCs alone or the MSCs+CPCs groups, CPCs are manufactured using each patient's own EMB samples. The methods for culture and subsequent production of CPCs are a modified version of the protocol previously used for SCIPIO (Cardiac Stem Cell Infusion In Patients With Ischemic Cardiomyopathy). 30 Briefly, EMBs are enzymatically digested with warm collagenase type II (Gibco number 17101) solution (final concentration 329 U/ mL diluted in Ham's F12) at 37°C. The digested solution is collected, washed, and plated in culture media to expand CPCs. Cells are expanded in culture for ≈3 to 4 weeks; when cell confluence >80% is attained, the culture is enriched for c-kit + cells using immunomagnetic beads (CD117 MicroBead Kit, Miltenyi Biotec). The c-kit + Be ≥21 and <80 y of age Have documented coronary artery disease with evidence of myocardial injury, LV dysfunction, and clinical evidence of heart failure Have a detectable area of myocardial injury defined as ≥5% LV involvement (infarct volume) and any subendocardial involvement by cMRI Have an EF ≤40% by cMRI Be receiving guideline-driven medical therapy for heart failure at stable and tolerated doses for ≥1 mo before consent Be a candidate for cardiac catheterization Have New York Heart Association class I, II, or III heart failure symptoms If a female of childbearing potential, be willing to use one form of birth control for the duration of the study, and undergo a pregnancy test at baseline and within 36 h before injection cMRI indicates cardiac magnetic resonance imaging; EF, ejection fraction; and LV, left ventricular.
CPCs are further expanded to generate the CPC product. Samples of the cell suspension taken from the last passage are characterized to assure that they meet predetermined specifications, including cell count, phenotype (CD117 positivity), mycoplasma testing, and other quality control tests, as indicated in Table 4 . Isolated CPC products are then suspended in cryoprotectant at 0.5 to 1.0×10 6 cells/mL and Table 2 .
Exclusion Criteria
To participate, a patient must not have:
Indication for standard-of-care surgery (including valve surgery, placement of LV assist device, or imminent heart transplantation), CABG procedure, and PCI.
Candidates cannot be UNOS 1A or 1B, and they must have documented low probability of being transplanted.
PCI within 3 mo of randomization CABG within 4 mo of randomization Valvular heart disease including mechanical or bioprosthetic heart valve, severe valvular (any valve) insufficiency/regurgitation within 12 mo of consent, and aortic stenosis with valve area ≤1.5 cm Poorly controlled blood glucose levels (HbA1c >10%)
Hematologic abnormality evidenced by hematocrit <25%, white blood cell <2500 per μL, or platelet count <100 000 per μL Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3× the ULN Coagulopathy (INR ≥1.3) not because of a reversible cause (eg, warfarin and factor Xa inhibitors). Patients who cannot be withdrawn from anticoagulation will be excluded.
HIV or active HBV or HCV
Allergy to radiographic contrast material that cannot adequately be managed by premedication Any other condition that, in the judgment of the Investigator or Sponsor, would impair enrollment, study product administration, or follow-up ALT indicates alanine amino tranferase; AST, aspartate amino transferase; CABG, coronary artery bypass grafting; CRT, cardiac resynchronization therapy; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; ICD, implantable cardioverter defibrillator; INR, international normalized ratio; LV, left ventricular; MRI, magnetic resonance imaging; PCI, percutaneous coronary intervention; TNF-α, tumor necrosis factor-α; ULN, upper limit of normal; UNOS, United Network for Organ Sharing; and Vo 2 max, maximal oxygen consumption. cryopreserved using a control rate freezer. The frozen vials are placed into the vapor phase of liquid nitrogen freezers and stored for at least 3 weeks. These products are not released until the required sterility testing has been completed on samples obtained before and after adding cryopreservation medium as outlined in Tables 4 and 5 . Media from the final CPC passage before product cryopreservation is likewise cryopreserved and sent to BRC.
MSC and CPC products are cryopreserved at the central cell manufacturing facility and stored in liquid nitrogen until ready to be shipped to the local cell processing laboratories. Cell products are transported to each clinical site via validated liquid nitrogen dry shipper within 1 week before the scheduled injection procedure. Local cell processors receive and prepare all products for administration. Placebo product consists of cell-free PlasmaLyte-A. All study products (MSCs alone, CPCs alone, MSCs+CPCs, and placebo) are provided to the treatment teams in packaging with identical appearance.
Biorepository Core
An optional central BRC is utilized for participants who provide additional informed consent. The goal is 3-fold (1) to provide storage of critical biomaterials (ie, participant peripheral blood, BM, MSC product, and CPC product), (2) to provide long-term integrity (up to 10 years) of these biospecimens and products, and (3) to provide management of immunologic, immunohistochemical, cellular, and molecular analyses of collected samples, as well as phenotypic and functional analyses of cells and plasma samples. The aim of the BRC is to identify factors that modulate disease progression and predict successful intervention and to gain insights into potential mechanisms of action of MSCs and CPCs as well as the relationship of MSC and CPC phenotypes to clinical outcomes. Samples collected and available for further analyses via ancillary studies are specified in Table 6 .
Study Product Delivery
Approximately 14 weeks after harvest, participants return to the cardiac catheterization laboratory for cardiac mapping and to receive the study product. The product undergoes cell counts and quality control testing before injection, as indicated in Table 5 . Each patient receives 15 intramyocardial, electromechanically-guided injections using the NOGA XP Mapping and Navigation System (Biological Delivery Systems, McKees Rocks, PA). Intervention groups receive 1 of 3 treatments: MSCs in 6 mL of PlasmaLyte-A (target dose, 150×10 6 cells; minimum dose, 75×10 6 cells), CPCs in 6 mL of PlasmaLyte-A (target dose, 5×10 6 cells; minimum dose, 0.8×10 6 ), or MSCs+CPCs (same doses as above) in 6 mL of PlasmaLyte-A. The placebo group receives 6 mL of cell-free PlasmaLyte-A. To maintain study blinding, if a patient randomized to MSCs+CPCs does not meet the minimum dose of CPCs, he/she will receive MSCs alone and conversely, if a patient does not meet the minimum dose of MSCs, he/she will receive CPCs alone; should both products fail to meet release criteria, the patient would receive placebo. If a patient in either the MSCs or CPCs alone groups does not meet the minimum dose, he/she will receive placebo. For statistical analysis purposes, all participants will be analyzed in the group to which they were randomized in accordance with the intention-totreat principle.
Injections are targeted to the border zones (5 to 10 mm regions adjacent to scar) identified by electromechanical mapping. Injections are placed so as to encircle the scar, with injection sites in both (1) the viable border zone surrounding the area of scar and (2) the scar adjacent to the viable border zone. Priority is given to viable zones with a unipolar voltage ≥7 mV and a premature ventricular contraction on the extension of the needle; some injections are made in the border zone with a voltage ≥4 mV without the requirement of a premature ventricular contraction. In addition, injection sites should satisfy the following 2 criteria: (1) perpendicular position of the catheter to the LV wall and (2) loop stability <4 mm. After proper placement of the catheter is confirmed, patients in the treatment groups receive a needle injection of 0.4 mL of solution (5 to 10×10 6 MSCs and 0.05 to 0.33×10 6 CPCs per injection) delivered over 60 s; those in the placebo group receive vehicle (0.4 mL of PlasmaLyte-A per injection). All patients are monitored overnight. A transthoracic 2D echo without contrast is performed within 6 hours after the procedure to evaluate for pericardial effusion, and blood samples for troponin measurements are collected ≈8 hours after the procedure and before discharge.
Outcomes
Visits occur at 1 day, 1 week, and 1, 3, 6, and 12 months after study product injection. A telephone contact takes place at 24 months to assess the patient's current medications, as well as morbidity and mortality. The primary end points assess feasibility, safety, and efficacy (Table 7 ). All adverse events grade 2 and higher, based on the Common Terminology Criteria for Adverse Events, are captured. These events include major adverse cardiac events related to HF (death, hospitalization for worsening HF, and exacerbation of HF not requiring hospitalization) and other significant clinical events. The feasibility of harvests, preparing and delivering the intended number of cells, and collecting cardiac MRI variables in patients with cardiac devices, is assessed.
Efficacy measures are obtained at baseline and at 6 and 12 months after study product injection. To comprehensively assess the efficacy of cell therapy, multiple end points have been selected from different categories of effects (domains; Table 7 ). MRI evaluations of LV function, LV structure (including LV volumes), and scar burden provide a comprehensive assessment of myocardial performance and morphology. MRI evaluations are performed at the time of screening, within 30 days before study product injection (baseline), and at 6 and 12 months after injection. The presence of a pacemaker or implanted defibrillator device is not a contraindication to MRI 33, 34 ; in these patients, the procedures recommended by the American Heart Association 33 are followed. All MRI analyses are performed in a core laboratory by investigators masked to treatment assignment and other patient data. Functional capacity encompasses maximal oxygen consumption (Vo 2 max, treadmill test; also assessed by a core laboratory blinded to treatment assignment), 6-minute walk test, and quality of life assessment (Minnesota Living With Heart Failure Questionnaire [MLHFQ]). We also assess clinical outcomes (measured by major adverse cardiac events related to heart failure and cumulative days alive and out of the hospital) and biomarkers of HF (NT-proBNP [N-terminal pro-B-type natriuretic peptide]).
Statistical Methods
The principal analysis will be based on an intention-to-treat assessment of the 3 cell therapies. The reasons for nontreatment of the anticipated small number of participants who are randomized but do not receive any treatment, or do not receive the randomly assigned treatment, will be tabulated. An as-treated evaluation placing patients in treatment groups based on what they received also will be conducted. Safety and feasibility data will be reported for participants in both the stage 1 lead-in study (n=18) and the stage 2 main cohort study (n=144). Exact testing for categorical variables and ANOVA for continuous variables will be used to evaluate the differences in baseline variables between treatment groups.
The change in every end point variable will be assessed using a repeated-measures general linear model for (1) the 6-month followup and (2) the 12-month follow-up. The dependent variable in this model will be the change in the treatment group; the independent *Tests done for release criteria specification before injection; for cell counts, the product must meet the minimum count for release.
†Based on recipient weight and product volume. variable will be the therapy group assignment. In addition, an interaction term consisting of the product of the CPCs and MSCs alone treatment arms will be included to assess the presence of cell therapy synergism. These analyses will provide the effect of each treatment for each assessment time period for each prospectively declared end point. Because the effects of MSCs and CPCs in these patients are unknown, and because this is not a pivotal trial, no adjustment for multiplicity will be used. This comprehensive analysis is based on the concept that early phase studies should provide the most complete and elaborative exposition and synthesis of data to guide the direction of future cell therapy research. 35 Sample sizes were chosen assuming a 20% attrition rate. Safety and feasibility data from stage 1 will be included in the formal analysis of the study.
Underestimation of the sample sizes needed to achieve the desired power would weaken the conclusions of the study, whereas overestimation would cause unnecessary expense of time and resources. Consequently, CONCERT-HF uses an adaptive design for finalizing the sample size. Specifically, the final sample size will be decided on the basis of the SD observed for each of the change in EF and of the change in infarct size between the baseline and 6-month data points in the control group. Two interim analyses will be performed when 34% and 66% of the control group have completed the 6-month data collection, and the data will be submitted to the Data and Safety Monitoring Board for review and recommendation.
Results
Study Design
CONCERT-HF is a phase II trial that assesses the effects of MSCs and CPCs, given alone or in combination, in patients with HF of ischemic cause. 
Changes in Study Design Resulting From Stage 1 (Lead-In Study)
Stage 1 was conducted to assess the feasibility and safety of the study procedures as well as the bioactivity of the products. One patient enrolled in stage 1 died during the EMB procedure because of right ventricular perforation resulting in hemopericardium and tamponade. In a study of patients with severe HF who undergo invasive procedures, adverse events are expected. 36 However, as a result of the unfortunate death during stage 1, several important changes to the design were made before the initiation of stage 2 to further reduce risk to study participants. The study protocol was modified as follows: (1) the EMB procedure was replaced with a sham procedure (RHC without EMB) in patients allocated to the control and MSCs alone groups; (2) stopping and halting thresholds were added on the day of harvest based on RHC pressures, heart rate, and New York Heart Association class; (3) more safety guidance was added for EMB harvesters, and harvesters are required to participate in ongoing best practices sessions aimed at enhancing the safety of the procedure; (4) pre-and post-EMB echocardiograms were added to detect new pericardial effusion; and (5) a postconsent case review by the Steering Committee was implemented for each potential participant before final eligibility determination. In addition, several procedural changes were made to maximize the ability to consistently reach the target CPC dose of 5×10 6 cells. 
Blinding of Investigators
As noted above, stage 2 includes sham EMB procedures for half of the study population (patients assigned to placebo or MSCs alone groups). In our judgment, it is unlikely that the EMB has any impact on patient outcomes, particularly because the study product is administered ≈ 3.5 months later. All patients undergo BMA, RHC, and NOGA-guided injections.
A sham protocol is followed for patients undergoing RHC without EMB so that they are not aware of whether an EMB is performed or not. Double-blinding is maintained by having separate blinded and unblinded study teams at each center; the team members directly involved in RHC/EMB procedures are not involved in any other part of the protocol, and all other members of the team are blinded to the therapy assignment.
Table 7. Study End Points
Feasibility assessment (the following measures will be reported)
Number and percent of patients who have:
Events between randomization and SPI that preclude the procedure CPC indicates c-kit+ cardiac progenitor cell; HF-MACE, major adverse cardiac events related to heart failure; LV, left ventricular; MLHF, Minnesota Living With Heart Failure; MRI, magnetic resonance imaging; MSC, mesenchymal stem cells; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SPI, study product injection; and Vo 2 max, maximal oxygen consumption.
Similarly, cardiac MRI and Vo 2 max end points are determined by core laboratories that are blinded to therapy assignment.
Management of Variability in MRI End Points
The power of CONCERT-HF is very sensitive to the variability of its end points. For example, the power to detect an increase of 6 absolute EF units is 81% if the SD is 8, but drops to 72% if the SD increases by only 1 U to 9. To minimize variability of MRI-based end points, the Data Coordinating Center and the MRI Core Lab monitor the SDs of individual centers (using only data in the control group). If center outliers are identified with respect to the SD of MRI end points, an effort will be made to reduce such variability, for example, by assessing technicians' ability to obtain images and providing additional training when needed, by evaluating changes in equipment at each center and need for software/hardware updates, by monitoring the rate of staff turnover and its impact, etc.
Group Sizes and Adaptive Design
One of the most innovative features of CONCERT-HF is the use of an adaptive design with regard to sample sizes (see Statistical Methods). The sample sizes described herein are tentative and were selected to ensure sufficient power to detect meaningful changes in end point measures. Power calculations were based on the variability encountered in previous trials in similar patient populations, including SCIPIO 30, 31 and TIME (Timing in Myocardial Infarction Evaluation), 37 LateTIME, 38 and SWISS-AMI (Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction). 39 According to these estimates, CONCERT-HF is adequately powered to detect significant changes in the following end points: a 5 unit increase in LVEF (power, 89%), a 4.5% decrease in myocardial scar size (93%), a 12 mL decrease in LV end-systolic volume (86%), and a 0.08 change in sphericity index (86%). Power for our other prospectively declared end points (ie, change in LV end-diastolic volume, Vo 2 max, 6-minute walk test, and MLHFQ score) is marginal at 70% to 80%, but given the anticipated interest in these outcomes, we are committed to reporting findings on these variables to the research community. In accordance with the adaptive design of the trial, final group sizes will be determined on the basis of 2 interim analyses (see Statistical Methods).
Discussion Study Design
Because data on the safety and feasibility of MSCs and CPCs have been reported previously, 16, 18, 30, 31 CONCERT-HF was designed as a phase II trial to assess not only feasibility and safety but also efficacy and to allow comparisons of each of the 4 treatment arms to the other 3. Selecting an appropriate primary end point, however, is difficult because the effects of MSCs and CPCs and their mechanism of action in humans remain unclear. Although LVEF has been used as the primary end point in many trials, failure to improve LVEF may not necessarily signify the absence of benefit, as exemplified by recent studies in which cell therapy reduced major adverse cardiac events 21, 23 or improved the 6-minute walking distance and MLHFQ score 16, 18 without improving LVEF. Accordingly, CONCERT-HF assesses multiple primary end points in various domains, including LV structure (eg, volumes), LV function, LV morphology (eg, scar volume), functional capacity, quality of life, clinical outcome, and biomarkers (Table 7) .
If the combination of MSCs and CPCs proves to be beneficial, the question will arise as to which cell type(s) is/are responsible for this effect. Answering this question requires a 4-arm design, which makes it possible not only to ascribe to MSCs, CPCs, or both, any favorable changes observed in the MSCs+CPCs group but also to determine whether the actions of MSCs and CPCs are additive or synergistic. An additional reason for including the CPCs alone group is to continue the evaluation of CPCs that was started in SCIPIO. 30, 31 Although in that trial patients receiving CPCs exhibited an improvement in LV function, scar size, functional capacity, and quality of life, 30, 31 SCIPIO was a small, open-label, first-in-human trial designed to assess feasibility and safety, not efficacy, in patients treated 3 to 4 months after bypass surgery. Therefore, it is important that the encouraging results of SCIPIO be rigorously tested in a phase II study using a randomized, doubleblind, placebo-controlled, multicenter design and without limiting the analysis to the postbypass surgery setting. In addition, whereas in SCIPIO the route of administration was intracoronary (i.c.), 30, 31 CONCERT-HF will provide information about the efficacy of CPCs administered transendocardially.
Preclinical and Clinical Studies of MSCs in Chronic Ischemic HF
MSCs are a particularly promising cell type for cardiac reparative therapy because of their availability, immunomodulatory properties, and track record of safety and efficacy. 4 In rodent and swine models of acute MI, administration of MSCs (both autologous 8, 9 and allogeneic 6, 7, 10, 11 ) enhances recovery of LV function. In swine models of chronic MI, MSCs (both autologous 12 and allogeneic 13 ), delivered either via epicardial injection 12 or transendocardial injection 13 , augment LV function. [12] [13] [14] In both settings, MSCs have been found to promote angiogenesis, decrease collagen deposition, and reduce myocyte apoptosis. 4 Importantly, MSCs interact with endogenous precursor cells (ie, CPCs) that may play an important role in cardiac repair 7 (vide infra). In the clinical arena, several studies have assessed the effects of MSCs, delivered via the transendocardial route, in patients with chronic ischemic HF. 4, 16, 18, [20] [21] [22] [23] 40, 41 The POSEIDON trial (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study) 16 assessed the safety and efficacy of autologous and allogeneic MSCs (no placebo control group was studied). Compared with baseline, at 1 year both autologous and allogeneic MSCs reduced scar size, but only autologous MSCs improved the 6-minute walk distance and MLHFQ score. Neither cell type increased LVEF. The TAC-HFT trial (The Transendocardial Autologous Cells [hMSC or hBMC] in Ischemic Heart Failure Trial) 18 evaluated autologous MSCs and unfractionated mononuclear BM cells. Compared with placebo at 1 year, both MSC and BM cells administration improved the MLHFQ score, but only MSCs improved regional LV function and 6-minute walk distance and reduced scar size (although they did not affect LVEF). Autologous MSCs incubated in vitro with a cardiogenic cocktail were found to have beneficial effects in the C-CURE trial 40 but not in the subsequent larger CHART-1 trial (Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure), 41 although in the latter a subgroup analysis suggested benefit in patients with LV end-diastolic volume >200 mL. A dose-escalating study of allogeneic STRO-1 bright mesenchymal progenitor cells found a reduction in HF-related major adverse cardiac events with the highest dose (150×10 6 cells) at 3 years, although there was no improvement in LVEF or LV volumes. 21 In all of these studies, 16, 18, 21, 40, 41 administration of MSCs was safe, and allogeneic cells did not elicit a detectable immune reaction.
Preclinical and Clinical Studies of CPCs in Chronic Ischemic HF
The ability of CPCs to alleviate LV dysfunction has been repeatedly demonstrated by several independent laboratories in various preclinical animal models of acute MI. 1 CPCs have also been shown to alleviate LV dysfunction and remodeling in rat 26, 27, 29, 42 and porcine 28 models of chronic MI, where they reduced not only scar size but also collagen deposition in the noninfarcted region. 26, 27, 2942 Because of the poor survival of transplanted cells, these effects have been ascribed to paracrine actions. 5, 43 The feasibility and safety of CPC therapy in the clinical setting are supported by the SCIPIO trial, a phase I, open-label trial of autologous CPCs in patients with chronic ischemic HF. 30, 31 In SCIPIO, CPCs were isolated and expanded in all 20 treated patients, and their i.c. infusion did not result in detectable adverse effects. At 2 years, CPC-treated patients exhibited improved LV function, functional status (New York Heart Association class), and MLHFQ score as well as a decrease in scar size. 30, 31 These results provide the rationale for studying the CPCs alone group in CONCERT-HF.
Preclinical Studies of the MSCs+CPCs Combination
The rationale for examining the combination of MSCs and CPCs stems from studies in porcine models in which administration of MSCs 3 days after MI-induced proliferation and differentiation of endogenous CPCs, 7 suggesting that an MSC-CPC interaction could be an important mechanism for the beneficial effects of MSCs. A subsequent study demonstrated that the combination of both cell types (ie, human MSCs and CPCs in immunosuppressed pigs), given transendocardially 14 days after MI, produced a greater reduction in scar size and improvement in LV function than each cell type alone, restoring diastolic and systolic LV function toward normal. 24 Additive beneficial effects of MSCs and CPCs have also been observed in rats. 25 Importantly, an additional porcine study was conducted, using autologous porcine cell combination therapy in a model of chronic MI, with cells delivered by NOGA catheter. 44 In this study, designed to recapitulate the delivery of cells that would occur in humans, the combination of MSCs and CPCs produced synergistic improvements in global and regional LV function relative to either cell type alone. 44 Together, these findings illustrate potentially important biological interactions between MSCs and CPCs that enhance cell therapeutic responses.
Rationale for Dose Selection
The target dose of MSCs in CONCERT-HF (150×10 6 ) was chosen on the basis of a dose-escalating trial of STRO-1 bright MPCs 21 (cells similar to MSCs), in which increasing doses of MPCs were associated with decreasing LV end-diastolic volume and LV end-systolic volume; the benefits were maximal at a dose of 150×10 6 cells, and no serious adverse events were reported. The safety of this dose is further supported by the fact that transendocardial injection of up to 200×10 6 MSCs was safe in preclinical porcine models 12, 13 and in the TAC-HFT 18 and POSEIDON trials, 16 and that intravenous doses of MSCs >200×10 6 cells have been used with no significant adverse effects. 15 The choice of the target dose of CPCs (5×10 6 ) reflects several considerations. Pig studies have shown that post-MI LV dysfunction is effectively ameliorated by 5×10 5 CPCs (a dose equivalent to ≈1×10
6 CPCs in humans) given by the i.c. route 28 CPCs in humans) is well-tolerated and produces no discernible adverse effects, as assessed by cardiac enzymes, myocardial function, and histology. 45 Thus, both preclinical and clinical evidence supports the notion that 5×10 6 CPCs should be effective in humans. Although higher doses could conceivably have greater efficacy, it would be challenging to reproducibly generate >5×10 6 CPCs from small amounts of cardiac tissue (10-20 mg). In conclusion, the target cell doses for CONCERT-HF (150×10 6 MSCs and 5×10 6 CPCs) have a strong safety profile, and there is considerable evidence for their potential to improve LV function and functional status in patients with HF.
Rationale for Using the Transendocardial Route of Administration
In previous studies in porcine models 7, 10, 11, 13, 24 and in humans, 16, 18, 21, 40, 41 transendocardial delivery of MSCs improved post-MI LV dysfunction and remodeling and (in clinical trials) functional capacity and MLHFQ score. The efficacy of intramyocardial injections of CPCs has been well-documented in rodents 25, 46 and in pigs. 1, 24 Although the only previous clinical trial of CPCs used i.c. infusion, 30, 31 we chose the transendocardial route for CPCs so that MSCs and CPCs could be delivered together. Transendocardial delivery was the route used for both cell types in the porcine studies that support the superiority of the combination over either cell type alone 7, 24 ; presumably, the juxtaposition of MSCs and CPCs promotes their interactions and may be the basis for their additive therapeutic effects. 4 Additional advantages of transendocardial delivery are that it is associated with greater myocardial retention 47 and makes it possible to reach regions distal to occluded coronary arteries.
Use of MRI in Patients With Cardiac Devices
MRI was selected over other imaging modalities, such as cardiac computed tomography and echocardiography, because it enables accurate, high-resolution assessment of myocardial scar, [48] [49] [50] is considered to be more reproducible for measuring LV function and volumes, 51, 52 and does not require any radiation exposure. One of the innovative aspects of CONCERT-HF is that MRI is used in patients with pacemakers and implanted defibrillator devices. Traditionally, these patients have been excluded because of the concern that the MRI examination may interfere with the function of the device and also because of the suboptimal image quality. 53, 54 However, studies have shown that with appropriate study candidate selection as well as software, equipment, and positioning optimization, MRI scanning can be performed safely in the presence of most cardiac devices without precluding acquisition of meaningful data. 33, 34 In this trial, extensive in-person and webinar-based training procedures were put in place at the local Radiology and Cardiology departments at each site under the supervision of the MRI Core lab to ensure patient safety and proper execution of the MRI protocol. The initial experience garnered at the MRI Core at Johns Hopkins University shows that, with the use of the exclusion criteria listed in Table 2 and appropriate software, [55] [56] [57] MRI scans can be obtained safely and the images can be analyzed for LV volumes and scar size in the vast majority of the cases. The experience of CONCERT-HF will generate new insights into the feasibility of using of MRI in patients with cardiac devices, which may have an important impact on the design of future studies not only of cell therapy but also of other interventions in HF. This information also may help obviate the problems stemming from the fact that patients may acquire devices over the course of a trial, which results in a significant drop-off of patients when serial MRI imaging is utilized to assess changes in LV function over time. 58 
Limitations
Because of the innovative nature of CONCERT-HF, the feasibility of certain aspects of the study is unclear. EMBs may not be sufficient to generate the target dose of CPCs (5×10 6 ) in all patients. The long interval between EMB and product injection (necessitated by the time needed for expansion) may result in some patient drop-out. Because this is the first trial to use MRI in patients with devices, the quality and reproducibility of images are not known. CONCERT-HF will furnish important feasibility information about these issues. An additional possible limitation is that, depending on variability, the trial may not have enough power to assess some of its end points.
In conclusion, CONCERT-HF is the first cell therapy clinical trial to evaluate the combination of 2 cell types. This study will provide important insights into the potential therapeutic utility of MSCs and CPCs, given alone and in combination, for patients with ischemic HF. In addition, the collection and storage of HF patient-specific biomaterials may offer important tools for future ancillary studies of regenerative medicine.
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